Keywords: restrictions, pfizer, chantix, reports, neuropsych, aes, prompt

Restrictions on Pfizer's Chantix as reports of neuropsych AEs prompt fresh concerns

Article | 02 June 2008

Print This

New safety concerns on Pfizer's Chantix (varenicline) could slow the sales expansion of the smoking-cessation drug and land the world ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in